These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 936381)

  • 1. Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
    Schmidt JD; Gibbons RP; Johnson DE; Prout GR; Scott WW; Murphy GP
    Urology; 1976 Jun; 7(6):602-10. PubMed ID: 936381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    Scott WW; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Saroff J; Murphy GP
    J Urol; 1976 Aug; 116(2):211-3. PubMed ID: 950706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
    Smalley RV; Bartolucci AA; Hemstreet G; Hester M
    J Urol; 1981 Feb; 125(2):191-5. PubMed ID: 7206052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
    Eagan RT; Utz DC; Myers RP; Furlow WL
    Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
    Merrin C; Etra W; Wajsman Z; Baumgartner G; Murphy G
    J Urol; 1976 Jan; 115(1):86-8. PubMed ID: 1107604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    Scott WW; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Saroff J; Murphy GP
    Trans Am Assoc Genitourin Surg; 1976; 68():24-8. PubMed ID: 1030548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study.
    Scott WW; Johnson DE; Schmidt JE; Gibbons RP; Prout GR; Joiner JR; Saroff J; Murphy GP
    J Urol; 1975 Dec; 114(6):909-11. PubMed ID: 1104900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
    Muss HB; Howard V; Richards F; White DR; Jackson DV; Cooper MR; Stuart JJ; Resnick MI; Brodkin R; Spurr CL
    Cancer; 1981 Apr; 47(8):1949-53. PubMed ID: 7194733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
    Herr HW
    J Urol; 1982 Mar; 127(3):462-5. PubMed ID: 7062419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estrogen-resistant prostatic cancer with bone metastases: palliative chemotherapy with 5-fluorouracil and cyclophosphamide].
    Küss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP
    Nouv Presse Med; 1978 Aug 26-Sep 2; 7(28):2478-9. PubMed ID: 80785
    [No Abstract]   [Full Text] [Related]  

  • 11. Early combined hormonal and chemotherapy for metastatic prostatic carcinoma.
    Servadio C; Mukamel E; Lurie H; Nissenkorn I
    Urology; 1983 May; 21(5):493-5. PubMed ID: 6857889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)].
    Kuss R; Khoury S; Richard F; Fourcade R; Frantz P; Capelle JP
    J Urol Nephrol (Paris); 1979; 85(10-11):649-55. PubMed ID: 94108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-hormone chemotherapy of prostatic cancer.
    Jones MA; Williams G
    Br J Urol; 1980 Apr; 52(2):127-30. PubMed ID: 7426962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
    Buell GV; Saiers JH; Saiki JH; Bergreen PW
    Urology; 1978 Mar; 11(3):247-50. PubMed ID: 636128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
    Murphy GP; Huben RP; Priore R
    Urology; 1986 Jul; 28(1):36-40. PubMed ID: 3523938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intermittent intravenous high-dose cyclophosphamide therapy for advanced prostatic cancer with distant metastasis].
    Kyakuno M; Yamaguchi S; Matsumiya K; Osafune M
    Hinyokika Kiyo; 1989 Nov; 35(11):1865-9. PubMed ID: 2618884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic carcinoma. relationship between primary tumor, histologic grade, and response to chemotherapy.
    Gibbons RP; Scott WW; Johnson DE; Prout GR; Schmidt JD; Murphy GP
    Urology; 1976 Sep; 8(3):222-6. PubMed ID: 969073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up.
    Servadio C; Savion M; Mukamel E
    Urology; 1987 Oct; 30(4):352-5. PubMed ID: 3660524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of chemotherapeutic responsiveness in Nb rat prostate cancer model. 5-fluorouracil, methotrexate, cyclophosphamide, and adriamycin.
    Drago JR; Goldman L; Gershwin ME
    Invest Urol; 1980 Jul; 18(1):80-1. PubMed ID: 7410017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.